| ipilimumab based treatment | ipilimumab alone | ipilimumab based treatment |
| ipilimumab alone | Ipilimumab (10 mg/kg) | ipilimumab plus gp100 | ipilimumab plus SoC |
| mML - 2nd line (L2) | | | | |
| mML - L2 - all population 11 | | | | |
| mML - L2 - BRAF mutant 1 | | | | |
Comparator:
vs ipilimumab alone; vs gp100; vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;